Gilead Sciences has secured approval from the United States health authorities for its new HIV prevention injection, Yeztugo, but concerns are growing over its steep price tag.

Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc.

The global HIV antivirals market is set for a period of robust growth, with a new forecast predicting its value will climb from an estimated USD 34.8 billion in 2025 to USD 53.6 billion by 2035. This ...

Patients with HIV who are resistant to all four antiretroviral drug classes face a higher risk for death than those who are ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to buy according to hedge funds. On July 25, the European Medicines Agency’s Committee for Medicinal Products for Human ...

The S&P 500 added 0.8% on Friday, Aug. 8, 2025, finishing just short of the closing record it set last week. Gilead Sciences ...

Stocks in the health-care industry rose as markets grew more confident that U.S. borrowing costs will fall, while companies in the sector pleased investors in their quarterly reports. Gilead Sciences ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit ...

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead Sciences is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic ...